Conditions: Behcet Disease
Keywords: Behçet's disease, intermediate uveitis panuveitis posterior uveitis uveitis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 118
Healthy volunteers: no

Brief summary:
The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to Behçet's disease during the 24 weeks of study therapy as compared to standard of care alone.

Detailed description:

Arms:
arm 1: AIN457 300 mg was administered in 2 subcutaneous (s.c.) injections of 150 mg each. every 2 weeks arm 2: AIN457 300 mg was administered in 2 subcutaneous (s.c.) injections of 150 mg e arm 3: Placebo was administered in 2 s.c. injections every 2 weeks

Interventions: intervention 1: AIN457 intervention 2: AIN457 intervention 3: Placebo
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None

Protocol document: